Tesamorelin + Ipamorelin
Peptide Stack · Combination ConceptGHRH analogue + GH-secretagogue dual-pathway research
What Is This Combination?
ERP catalog context: Tesamorelin 12 mg + Ipamorelin 6 mg -- total 18 mg
A pairing of Tesamorelin, an FDA-approved GHRH analogue for a narrow indication, with Ipamorelin, a receptor-distinct GH-secretagogue -- grounded in general dual-pathway GH-release physiology, not a trial of this exact formulation, and not a general weight-loss or anti-aging combination.
The Concept
Tesamorelin supplies a GHRH-receptor signal; Ipamorelin adds a receptor-distinct GH-secretagogue signal. General GHRH-plus-GHS physiology provides the conceptual rationale for pairing the two pathways. No direct published trial validates this exact formulation, and Tesamorelin's own approved-indication boundary is not expanded by adding a second component.
Meet the Components
Tesamorelin
12 mgGHRH-analogue signaling arm
Tesamorelin is an FDA-approved GHRH analogue that stimulates endogenous growth-hormone secretion. Its approved indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for general weight loss, and this combination page does not extend that indication to any other population or use.
Randomized-trial evidence applies specifically to the FDA-approved indication and population; it does not establish general weight-loss, anti-aging, bodybuilding, or athletic benefits, combined or otherwise. See the standalone Tesamorelin page for its full evidence and indication boundary.
Strong evidence, narrow approved indication
View Tesamorelinresearch profile →Ipamorelin
6 mgreceptor-distinct GH-secretagogue signaling arm
Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist, providing a growth-hormone-release pathway distinct from Tesamorelin's GHRH-receptor mechanism.
See the standalone Ipamorelin page for its full evidence summary.
Independent human secretagogue evidence
View Ipamorelinresearch profile →How the Roles Fit Together
What the Combination Is Intended to Address
Evidence-Supported Conceptual Domains
- GH/IGF-1 axis
- endocrine physiology
- visceral-adiposity biology
- body-composition research context
Community-Use Themes
The themes below are editorial summaries of commonly discussed community-use patterns. They are not controlled clinical evidence, systematically sourced community data, or established benefits.
- abdominal-fat discussions outside the approved population(editorial-summary)
- sleep and recovery discussions(editorial-summary)
- body composition discussions(editorial-summary)
- anti-aging and wellness discussions(editorial-summary)
Concerns & Evidence Gaps
Safety Consideration
Overlapping GH/IGF-1 downstream stimulation from two GH-axis-acting components has not been directly studied together.Safety Consideration
Elevated IGF-1 is a recognized consideration with GH-axis stimulation generally.Safety Consideration
Fluid retention is a recognized consideration with GH-axis stimulation generally.Safety Consideration
Glucose intolerance is a recognized consideration with GH-axis stimulation generally.Safety Consideration
Long-term combination safety is unknown.Safety Consideration
The fixed ratio used in this combination is not derived from any clinical optimization study.
Why Separate Components May Sometimes Be Preferable
Presented as a scientific/practical tradeoff, not a recommendation.
Favoring Separate Administration
- Tesamorelin already has defined single-drug pharmacology and an approved indication; the second secretagogue may not be necessary for every research question involving Tesamorelin alone.
- Independent administration keeps Tesamorelin's approved-indication evidence base cleanly separate from an unapproved combination use.
- Separate dosing allows either component to be adjusted or discontinued without affecting the other.
- No evidence-derived optimal ratio between the two components has been established.
Favoring the Fixed-Ratio Blend
- A single combined vial is more convenient to source and administer than two separate components on two schedules.
Convenience is not evidence of biological superiority.
Evidence Boundary
The components of this combination have been investigated individually to varying degrees. Evidence for an individual component does not automatically establish the safety, efficacy, compatibility, or synergy of the exact combination. Where direct combination studies exist, MitoCore identifies that explicitly. Where they do not, the page describes the biological rationale for the combination rather than presenting the stack itself as a validated therapeutic intervention.
Exact-combination status: General GHRH-plus-GHS dual-pathway physiology is described in the broader research literature. No direct published trial of this exact Tesamorelin-plus-Ipamorelin formulation was located; Tesamorelin's own randomized-trial evidence applies to its narrow FDA-approved indication and population, not to this combination or to general use.
Limitations: This 'limited' status refers to general dual-pathway growth-hormone-release physiology, not a clinical trial of this exact formulation. It does not establish that adding Ipamorelin extends Tesamorelin's approved indication, improves its effect, or is safe or effective outside that indication and population.
Component evidence: Evidence strength varies by component -- Tesamorelin carries strong evidence within a narrow approved indication and population; Ipamorelin's own evidence base is separate. See each component's own standalone page.
Explore the Components
Each component's full evidence base lives on its own standalone research profile.
Tesamorelin
Tesamorelin is an FDA-approved growth hormone-releasing hormone analogue for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Randomized trials support reduction of visceral adipose tissue in that specific population, with additional population-specific research on liver fat. It is not indicated for general weight loss, and evidence does not establish anti-aging, bodybuilding, cognitive, athletic, or longevity benefits.
View research profile →Ipamorelin
Ipamorelin is a ghrelin-receptor agonist and growth-hormone secretagogue. Human research confirms that it can trigger an acute GH pulse, but the principal phase 2 clinical trial for postoperative ileus did not meet its primary efficacy endpoint. Evidence does not establish common claims involving sleep, recovery, body composition, or anti-aging, and FDA has highlighted serious safety and product-characterization concerns for compounded injectable use.
View research profile →Disclaimer
See the anecdotal notice above for community-discussion context.
This page does not establish combination efficacy, safety, or compatibility beyond what is explicitly cited above. Always review each component's own standalone research profile for its full evidence base.